Safilens: FDA approves hyaluronic acid release in lenses

Another success for Safilens, an important and constantly-growing Italian company, which is now looking to capture also the US market. Thanks to its recent success on the ophthalmic market by acquiring the patent for the United States, Safilens can now offer American customers and patients the innovative Safe Gel technology based on hyaluronic acid. The go-ahead by the Food and Drug Administration, the agency that controls the sale of medical and health products in the United States, has eliminated all obstacles for the distribution of contact lenses in the States.

“We are really proud of this well-deserved success”, stated Safilens president Fernando Garbellotto. “We have worked very hard and invested in research and innovation to obtain the Safe Gel line and we can now state that Safilens is the first Italian contact lens producer to have been given this possibility by the FDA”.

Wellbeing and comfort is guaranteed for all American contact lens wearers; thanks to the hyaluronic acid-based natural biopolymer JALURONATE – GEL, they can maintain and restore the pseudomucinous volume of the lacrimal film to ensure constant and unaltered tear production as well as a balanced supply of oxygen.

The Safe Gel line of Safe Gel 7 Days and Safe Gel 1 Day, in addition to the more recent Safe Gel Toric 1 day for astigmatism, will be distributed in the US by Two Tower Frames, the exclusive distributor of the Safe Gel technology in the USA, Canada and Central America. “We were anxiously waiting for this official announcement by the FDA and finally it came in January” said Eric Sharvelle, president of Two Tower Frames. “We can at last start to think about really commercializing such a high quality product that American consumers will be quick to appreciate”.